Halda Therapeutics
Nilesh Zaware has a diverse work experience in the field of scientific research and academia. Nilesh is currently working as a Principal Scientist at Halda Therapeutics since 2021. Prior to this, they held multiple roles at the Icahn School of Medicine at Mount Sinai, including Adjunct Assistant Professor, Research Assistant Professor, Instructor, and Postdoctoral Fellow. At Mount Sinai, they also served as the President of the Student-Postdoc Association. Nilesh has also worked as an Adjunct Assistant Professor at Long Island University and Brooklyn College. Nilesh gained industry experience as an Intern at Mount Sinai Innovation Partners, where they participated in the process of bringing new healthcare technologies to the market. Nilesh began their career as a Postdoctoral associate at Duquesne University and the University of Pittsburgh. Nilesh completed their graduate studies as a Graduate student at Duquesne University.
Nilesh Zaware completed their MS-PhD in Medicinal Chemistry from Duquesne University, where they studied from 2003 to 2008. Prior to that, their educational background includes attending Bharati Vidyapeeth and Vidya Prasarak Mandals, but specific degree names or fields of study are not provided for these institutions.
This person is not in the org chart
This person is not in any offices
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.